5 reasons to encourage anti-SARS-CoV-2 vaccination in patients with rheumatic diseases.

Autor: Motta, Francesca, Selmi, Carlo, De Santis, Maria
Předmět:
Zdroj: Expert Review of Clinical Immunology; Dec 2021, Vol. 17 Issue 12, p1241-1244, 4p
Abstrakt: Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. In a multicentre observational study including 686 patients, IgG antibody levels against SARS-CoV-2 spike S1/S2 proteins were measured 2-6 weeks after completion of a two-dose regimen, 3 weeks apart, of BNT162b2 mRNA vaccine and compared with those of 121 controls from the general population. [Extracted from the article]
Databáze: Complementary Index